Browsing by Author "Celik, OK"
Now showing 1 - 12 of 12
Results Per Page
Sort Options
Item Do we overtreat or undertreat the axillary region in lymph node-positive breast cancer patients?Celik, OK; Hoca, S; Bölükbasi, Y; Olacak, N; Haydaroglu, AItem Hipofractionated radiotherapy for locally-advancedCelik, OK; Parvizi, M; Ozkok, S; Yalman, D; Cok, GItem Bone mineral density in women with breast cancerCelik, OK; Turan, Y; Kocaaga, Z; Gürgan, A; Duransoy, AItem Evaluation of Daily Patient Position Accuracy and Calculation of Setup Errors with Skin Markers and Surface-Guided Radiotherapy (SGRT) in Breast CancerBakicierler, G; Celik, OK; Sindir, B; Can, ÖD; Akgüngör, KItem chemoradiotherapy induced hypomagnesemia is associated with superior survival in laryngeal cancerCelik, OK; Uncu, O; Ayaydin, BItem The Treatment Outcomes of Oligometastatic Colorectal Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Multi-Institutional Analysis TROD 02-008Guler, OC; Hurmuz, P; Atalar, B; Guney, YY; Saglam, EK; Akyurek, S; Bolukbasi, Y; Güral, Z; Tugrul, F; Korcum, AF; Sen, CA; Yildirim, BA; Oksuz, DC; Celik, OK; Kurt, M; Guzeloz, Z; Yavas, G; Ozyigit, G; Aksu, MG; Onal, CItem Clinical and prognostic features of plasmacytomas: A multicenter study of Turkish Oncology Group-Sarcoma Working PartyKilciksiz, S; Celik, OK; Pak, Y; Demiral, AN; Pehilvan, M; Orhan, O; Tokatli, F; Agaoglu, F; Zincircioglu, B; Atasoy, BM; Ozseker, N; Yersal, O; Niang, U; Haydaroglu, ATo identify the outcomes of prognostic factors of solitary plasmacytoma mainly treated with local radiotherapy (FIT). The data were collected from 80 patients with solitary plasmacytoma (SP). Forty patients (50.0%) received radiotherapy (FIT) alone while 38 of them (47.5%) were treated with surgery (S) and FIT. The median radiation dose was 46 Gy (range 30-64). The median follow up was 2.41 years (range 0.33-12.33). Ten-year overall survival (OS) and local relapse-free survival (LRFS) were 73% and 94%, respectively. The median progression-free survival (PFS) and multiple myeloma-free survival (MMFS) were 3.5 years and 4.8 years, respectively. On multivariate analyses, the favorable factors were radiotherapy dose of >= 50 Gy and RT + S for PFS and younger age for MMFS. For the patients with medullary plasmacytoma, the favorable factor was younger age for MMFS. RT at >= 50 Gy and RT + S may be favorable prognostic factors on PFS. Younger patients, especially with head-neck lesion and without pre-RT macroscopic tumor, seem to have the best outcome when treated with RT +/- S. Progression to MM remains as the main problem especially for older patients.Item The Treatment Outcomes of Patients with Cervical Esophageal Carcinoma Undergoing Definitive Chemoradiotherapy: A Multi-Institutional Analysis TROD 01-005Guler, OC; Oymak, E; Yazici, G; Akagunduz, OO; Cetinayak, O; Erpolat, P; Aksoy, A; Duzova, M; Yildirim, BA; Kurt, M; Canyilmaz, E; Akyurek, S; Atalar, B; Yavas, G; Oksuz, DC; Saglam, EK; Celik, OK; Cengiz, M; Onal, CItem Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 studyGuler, OC; Oymak, E; Yazici, G; Akagunduz, OO; Cetinayak, O; Erpolat, P; Aksoy, A; Duzova, M; Yildirim, BA; Kurt, M; Canyilmaz, E; Yavas, G; Akyurek, S; Oksuz, DC; Saglam, EK; Celik, OK; Ozyar, E; Cengiz, M; Onal, CThe aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy -confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni-and multivariable analyses. The median age of the entire cohort was 56 years (range: 26-87 years). All patients received definitive radiotherapy with a median total dose of 60 Gy, and 52% of the patients received cisplatin-based concurrent chemotherapy. The 2-year OS, PFS, and LRFS rates were 58.8%, 46.9%, and 52.4%, respectively, with a median follow-up duration of 41.6 months. Patients' performance status, clinical nodal stage, tumor size, and treatment response were significant prognostic factors for OS, PFS, and LRFS in univariate analysis. Non-complete treatment response was an independent predictor for poor OS (HR = 4.41, 95% CI, 2.78-7.00, symbolscript < 0.001) and PFS (HR = 4.28, 95% CI, 2.79-6.58, symbolscript < 0.001), whereas poor performance score was a predictor for worse LRFS (HR = 1.83, 95% CI, 1.12-2.98, symbolscript = 0.02) in multivariable analysis. Fifty-two patients (29.7%) experienced grade II or higher toxicity. In this multicenter study, we demonstrated that definitive CRT is a safe and effective treatment for patients with CEC. Higher radiation doses were found to have no effect on treatment outcomes, but a better response to treatment and a better patient performance status did.Item Patterns of care for lung cancer in radiation oncology departments of TurkeyDemiral, A; Alicikus, ZA; Ugur, V; Karadogan, I; Yoney, A; Andrieu, MN; Yalman, D; Pak, Y; Aksu, G; Ozyigit, G; Ozkan, L; Kilciksiz, S; Koca, S; Caloglu, M; Yavuz, A; Caglar, H; Beyzad-eoglu, M; Igdem, S; Serin, M; Kaplan, B; Koc, M; Korkmaz, E; Celik, OK; Kinay, MItem Symptomatic and edoscopic response in primary lung cancer patients following endobronchial brachytherapy: An evaluation of 166 casesCelik, OK; Goksel, T; Mogulkoc, N; Anacak, Y; Cok, G; Haydaroglu, A; Ozkok, SItem Risk Assessment of Xerostomia Using F18 FDG PET/CT Metabolic Parameters After Radiotherapy in Head And Neck CancersBozdemir, B; Mutevelizade, G; Aydin, N; Suner, AF; Celik, OK; Kocabasoglu, E; Kahya, M; Bakicierler, G; Gumuser, G; Bilgin, ES